Scotiabank reiterated its “Outperform” rating on Teva Pharmaceutical Industries and raised its 12-month price target by approximately 14%, reflecting confidence in the company’s generics and specialty pipeline. The upgrade follows Teva’s successful delivery on strategic cost-savings initiatives and positions the stock among the top large-cap pharmaceutical names covered by the bank. Analysts cited Teva’s diversified portfolio and improving balance sheet as primary catalysts for the revised outlook.

In its latest quarterly report, Teva posted a double-digit year-over-year increase in net profit, driven by a one-time milestone fee from a late-stage inflammatory bowel disease collaboration and robust growth of Austedo, its movement disorder treatment. Revenue from branded products rose by over 20%, offsetting softer generic volumes in key U.S. markets. The milestone payment alone contributed more than 10% of total quarterly earnings, underscoring the value of Teva’s specialty partnerships.

Management provided guidance for fiscal 2026 that anticipates low-single-digit revenue growth and expanded adjusted EBITDA margins, supported by continued Austedo momentum and new launches in respiratory and central nervous system therapies. Teva’s global market share in generics remains above 10%, and the company plans to reinvest a portion of free cash flow into high-value specialty research programs. Trading volume has averaged over two million shares per session, reflecting sustained investor interest in Teva’s turnaround strategy.